# Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

> **NCT00225290** · PHASE3 · TERMINATED · sponsor: **TTY Biopharm** · enrollment: 230 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Thalidomide(Thado)

## Key facts

- **NCT ID:** NCT00225290
- **Lead sponsor:** TTY Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 230 (ESTIMATED)
- **Why stopped:** slowly recruitment rate
- **Last updated:** 2011-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225290, "Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00225290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*